Theator Achieves HITRUST CSF® Certification for Ensuring the Highest Standards of Privacy and Compliance to Partner Healthcare Institutions

Theator, the creator of Surgical Intelligence, announced today that it has achieved the HITRUST Cyber Security Framework (CSF) certification for practicing security protocols that meet both risk- and compliance-based HITRUST CSF requirements.

HITRUST CSF is a certifiable framework that provides organizations with a comprehensive, flexible, and efficient approach to regulatory compliance and risk management. Due to the sensitive nature of healthcare data specifically and the rise in healthcare breaches this year, HITRUST CSF certification is essential for health technology vendors to instill confidence in security measures and protect the very patients they aim to help. This accomplishment demonstrates the high level of importance Theator places on privacy, security, and compliance and solidifies Theator as a leader in all three areas. With HITRUST CSF certification, Theator is committed to maintaining the highest levels of nationally and internationally accepted security and privacy-related regulatory adherence in ongoing and future projects.

“Surgical Intelligence increases visibility into the OR to better evaluate surgical best practices, so we, at Theator, have a responsibility to provide our partners and their patients with the highest levels of protection,” said Dotan Asselmann, CTO and Co-founder of Theator. “HITRUST CSF certification instills that confidence in Theator’s technology and accelerates our mission to define a new gold standard in surgical care.”

Theator created the category of Surgical Intelligence to increase OR visibility and eliminate the widespread variability and disparity plaguing the surgical field. Theator’s first-of-its-kind Surgical Intelligence Platform institutionalizes automatic and routine surgical video capture, layering footage with AI-powered analysis of every operation. Surgical stakeholders access actionable insights to deliver optimized patient outcomes, ultimately enhancing surgical best practices and raising overall standards of care.

Most recently, in July 2022, Theator announced it had closed out its Series A funding with $39.5M, having now raised a total of $42.5M. In the last year, Theator has collaborated with Mayo Clinic and partnered with the Canadian Association of General Surgeons (CAGS), adding further prestige to the burgeoning list of innovative medical institutions and surgical societies adopting Surgical Intelligence. Last December, the company was named on CB Insights’ prestigious Digital Health 150 list of the 150 most innovative digital health startups in the world, highlighting industry recognition of Surgical Intelligence as a distinct category for the first time.

SourceTheator

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”